Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis (CAMELOT)

We did not focus exclusively on the blood pressure question. CAMELOT was more about what therapeutic strategy should be used with CAD patients.[1] We knew that some people advocated the use of angiotensin-converting enzyme (ACE) inhibitors, and although the results of the Heart Outcomes Prevention Evaluation (HOPE)[2] were not yet available when CAMELOT was set up, there was a lot of support for the potential benefits. In addition, a pilot study, the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT),[3] coordinated at the University of Michigan Medical Center (Ann Arbor), showed that amlodipine could reduce major cardiovascular events in patients who were not particularly hypertensive.